Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
Compared to TDF, peginterferon alfa 2a may has more therapeutic efficacy in hepatitis B
surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b
patients. We design this study to compare the effectiveness and safety between the
combination therapy of TDF and peg-IFN with TDF alone in NAs experienced patients with HBV
related liver fibrosis. Especially the improvement of liver fibrosis and the occurrence of
long-term end-stage liver disease such as cirrhosis, liver cancer, etc.